Milan, Italy – June 19, 2006 – Newron Pharmaceuticals SpA, a late-stage discovery and development company focusing on novel CNS therapies, today announced the preliminary results of a six-month phase III trial with its leading drug, safinamide, in development as an adjunct treatment for Parkinson’s patients.
